DA
Therapeutic Areas
Xenon Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| XEN1101 | Major Depressive Disorder (MDD) | Phase 3 |
| XEN496 (NBI-921352) | KCNQ2 Developmental and Epileptic Encephalopathy | Phase 2/3 |
| XEN053 | Undisclosed Target | Preclinical |
Leadership Team at Xenon Pharmaceuticals
IM
Ian Mortimer
President, Chief Executive Officer, and Director
SA
Sherry Aulin
Chief Financial Officer
DC
Dr. Christopher Kenney
Chief Medical Officer
DS
Dr. Simon Pimstone
Co-Founder and Director
DM
Dr. Michael Hayden
Co-Founder, Chief Scientific Officer, and Director
DE
Dr. Elizabeth (Liz) Garofalo
Executive Vice President, Head of Clinical Development
DJ
Dr. Juan Carlos Lopez
Vice President, Discovery
DG
Dr. Gary Patou
Chief Development Officer
FJ
Felix J. Baker
Director
DD
Dr. David W. Crabb
Director